Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Universal Music Group Rejects Pershing Square Takeover Proposal 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc. (NASDAQ: VERV) in a deal valued at up to $1.3 billion, according to the Financial Times. This move underscores Eli Lilly’s aggressive expansion into genetic medicine as it seeks to boost its pipeline of experimental drugs.
Verve Therapeutics’ stock skyrocketed nearly 73% in after-hours trading, reaching $10.76, following the news. The proposed deal would include a $1 billion upfront payment and an additional $300 million tied to performance-based milestones. The acquisition price values Verve at approximately double its market capitalization of just over $500 million as of Monday's close.
The Boston-based Verve specializes in in vivo gene editing treatments aimed at cardiovascular disease. Eli Lilly’s interest lies in leveraging Verve’s proprietary CRISPR-based technology to diversify and enhance its R&D capabilities.
This potential acquisition adds to Eli Lilly’s recent M&A streak. Earlier in 2025, the pharmaceutical giant acquired Scorpion Therapeutics for $2.5 billion and SiteOne Therapeutics for $1 billion, signaling a clear strategy to invest in innovative biotech platforms.
Despite broader industry challenges, Eli Lilly continues to outperform competitors, driven by strong sales of its diabetes and weight-loss drugs Mounjaro and Zepbound. By acquiring Verve, Lilly aims to strengthen its long-term competitiveness in the fast-evolving field of gene therapies.
Investors are watching closely as the deal, if finalized, could mark a major turning point for both companies and the broader gene editing space. Eli Lilly’s push into advanced therapeutics reaffirms its leadership in shaping the future of precision medicine and biopharmaceutical innovation.
